Dr. Burak Berber
Co-Founder, Biodecode
Türkiye
Biography
Dr. Burak Berber, a co-founder of BIODECODE Software and Health Services Inc. (BIODECODE Yazılım ve Sağlık Hizmetleri A.Ş.), continues his academic career as a faculty member at Eskişehir Technical University. In 2024, he completed his PhD by investigating the role of fatty acids in brain metabolism within a project conducted under a TÜBİTAK 2214 international research fellowship, in collaboration between Cold Spring Harbor Laboratory (CSHL) and the Medical University of South Carolina (MUSC). His areas of expertise include molecular docking, in silico drug analyses, gene editing, bioinformatics analyses, and a wide range of in vivo and in vitro experimental methods. As of 2025, Dr. Berber has an H-index of 7 and has published 10 SCI-indexed articles and 1 TR-Dizin article in reputable journals in his field.
Title: The importance of genetic analyses in drug selection and treatment responses
Abstract
Recent advances in clinical pharmacogenetics aim to improve treatment efficacy and reduce adverse drug reactions by guiding drug selection, dosage adjustment, and therapeutic monitoring based on patient-specific genetic information. With the growing availability of genomic data and the integration of clinical guidelines, pharmacogenomic testing has increasingly become a clinical decision support tool across multiple disciplines, including oncology, cardiology, psychiatry, immunology, and critical care. Different countries have adopted diverse strategies regarding reimbursement policies, clinical guideline integration, and laboratory infrastructure when implementing pharmacogenomic practices in healthcare systems. Global frameworks such as CPIC, DPWG, and PharmGKB continue to play a key role in harmonizing these approaches and advancing personalized medicine.
This presentation will focus on current developments in pharmacogenetic testing, clinical applications, and international strategies for adopting pharmacogenomic practices. Furthermore, BIODECODE’s next-generation pharmacogenomic analysis platform will be introduced, highlighting its comprehensive gene panel, WGS-based deep sequencing capability, variant annotation pipeline, clinical reporting workflow, and integration features for healthcare providers and researchers. Case-based examples and clinical decision support perspectives will illustrate the platform’s contribution to improving healthcare outcomes.
Within this comprehensive scope, the importance of pharmacogenetic analyses in drug selection and treatment response, as well as future directions for health policy integration and clinical adoption, will be discussed.